Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib extension study in Philadelphia chromosome-positive chronic myeloid leukemia
NL-OMON47755Phase 4Active, not recruiting
- Sponsor
- Pfizer
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of bosutinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Pfizer. Primary endpoints: Long-term safety of bosutinib, Diarrhea incidence after switch to commercial formulation and 7 more. Started Feb 2014; status: active, not recruiting.
02
Drugs
bosutinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON47755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47755.